Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome - Overview
Short Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Short Bowel Syndrome - Companies Involved in Therapeutics Development

9 Meters Biopharma Inc
Amogen Pharma Pvt Ltd
Applied Molecular Transport Inc
enGene Inc
Entera Bio Ltd
Hanmi Pharmaceuticals Co Ltd
Huons Global Co Ltd
Micelle BioPharma Inc
po Pharmaceuticals Inc
OPKO Health Inc
PhaseBio Pharmaceuticals Inc
QuiaPEG Pharmaceuticals AB
Surrozen Inc
Takeda Pharmaceutical Co Ltd
Tasly Pharmaceutical Group Co Ltd
VectivBio Holding AG
Worphmed Srl
Zealand Pharma AS
Short Bowel Syndrome - Drug Profiles
apraglutide - Drug Profile
Product Description
Mechanism Of Action
Bispecific Monoclol Antibody for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
crofelemer DR - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Short Bowel Syndrome - Drug Profile
Product Description
Mechanism Of Action
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
GLP-2 - Drug Profile
Product Description
Mechanism Of Action
GLP-2 - Drug Profile
Product Description
Mechanism Of Action
GLP2-ELP - Drug Profile
Product Description
Mechanism Of Action
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
HL-06 - Drug Profile
Product Description
Mechanism Of Action
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
melatonin - Drug Profile
Product Description
Mechanism Of Action
MOD-1501 - Drug Profile
Product Description
Mechanism Of Action
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
QPG-1030 - Drug Profile
Product Description
Mechanism Of Action
SC-403 - Drug Profile
Product Description
Mechanism Of Action
teduglutide - Drug Profile
Product Description
Mechanism Of Action
teduglutide - Drug Profile
Product Description
Mechanism Of Action
vuroletide - Drug Profile
Product Description
Mechanism Of Action
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
Nov 03, 2022: VectivBio announces completion of enrollment for colon-in-continuity (CIC) cohort of STARS pivotal phase 3 study investigating apraglutide in short bowel syndrome with intestil failure (SBS-IF)
Oct 13, 2022: VectivBio reports positive interim clinical data from STARS nutrition, a phase 2 study investigating apraglutide in short bowel syndrome with intestil failure patients (SBS-IF) with Colon-In-Continuity (CIC)
Oct 03, 2022: Zealand Pharma reports data from Phase III short bowel syndrome trial
Sep 26, 2022: 9 Meters Biopharma announces positive fil results from phase 2 vibrant study and successful end-of-phase 2 meeting with FDA for vuroletide in short bowel syndrome
Jul 13, 2022: 9 Meters Biopharma to participate in the William Blair Biotech Focus Conference 2022
Jun 30, 2022: 9 Meters Biopharma announces debt facility to support phase 3 study of vuroletide for short bowel syndrome
Jun 30, 2022: 9 Meters Biopharma announces positive prelimiry results from phase 2 study of vuroletide in short bowel syndrome
Jun 01, 2022: NICE recommends Revestive (teduglutide) for the treatment of adults and children living with Short Bowel Syndrome (SBS)
May 05, 2022: 9 Meters Biopharma to present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium
Mar 29, 2022: VectivBio presents new clinical data supporting apraglutide for treatment of short bowel syndrome with intestil failure (SBS-IF) patients who have rel dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference
Mar 21, 2022: 9 Meters Biopharma to present the clinical milestones for vuroletide at the Maxim Group 2022 Virtual Growth Conference
Feb 28, 2022: 9 Meters Biopharma provides clinical update on late-stage pipeline product vuroletide for short bowel syndrome
Jan 20, 2022: Zealand Pharma completes enrollment in EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
Dec 16, 2021: Zealand Pharma announces enrollment of last patient needed for interim alysis of EASE-SBS 1 phase 3 trial assessing Glepaglutide in patients with short bowel syndrome
Dec 13, 2021: European Medicines Agency grants Orphan Drug Desigtion for crofelemer to po EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Short Bowel Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Short Bowel Syndrome, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Short Bowel Syndrome - Pipeline by 9 Meters Biopharma Inc, 2022
Short Bowel Syndrome - Pipeline by Amogen Pharma Pvt Ltd, 2022
Short Bowel Syndrome - Pipeline by Applied Molecular Transport Inc, 2022
Short Bowel Syndrome - Pipeline by enGene Inc, 2022
Short Bowel Syndrome - Pipeline by Entera Bio Ltd, 2022
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Short Bowel Syndrome - Pipeline by Huons Global Co Ltd, 2022
Short Bowel Syndrome - Pipeline by Micelle BioPharma Inc, 2022
Short Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, 2022
Short Bowel Syndrome - Pipeline by OPKO Health Inc, 2022
Short Bowel Syndrome - Pipeline by PhaseBio Pharmaceuticals Inc, 2022
Short Bowel Syndrome - Pipeline by QuiaPEG Pharmaceuticals AB, 2022
Short Bowel Syndrome - Pipeline by Surrozen Inc, 2022
Short Bowel Syndrome - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, 2022
Short Bowel Syndrome - Pipeline by VectivBio Holding AG, 2022
Short Bowel Syndrome - Pipeline by Worphmed Srl, 2022
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, 2022
Short Bowel Syndrome - Dormant Projects, 2022
Short Bowel Syndrome - Discontinued Products, 2022